The complex effects of altered CME capacity on oncogenesis may depend on the tumor cell type as reflected by the fact that high FCHSD2 levels are correlated with increased survival in NSCLC [27], whereas elevated FCHSD2 may hamper survival in acute myeloid leukemia [34]. Here, FCHSD2 is linked to non-small cell lung carcinoma.